City of St. Louis Selects Cardiac Science as Exclusive Provider of AEDs for Public Access Defibrillation Program
January 20 2005 - 1:30AM
PR Newswire (US)
City of St. Louis Selects Cardiac Science as Exclusive Provider of
AEDs for Public Access Defibrillation Program St. Louis Joins a
Growing List of Major U.S. Cities to Partner With Cardiac Science
on Comprehensive AED Deployment IRVINE, Calif., Jan. 20
/PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a
leading manufacturer of life-saving automatic public-access
defibrillators (AEDs), announced today that it has been selected as
the exclusive provider of AEDs and comprehensive AED/CPR training
and AED program management services for a city-wide Public Access
Defibrillator (PAD) program launched by the City of St. Louis,
Missouri. To initiate the program, approximately 90 Powerheart(R)
AED G3s were purchased from Cardiac Science. St. Louis's new PAD
program makes it the latest major U.S. city to partner with Cardiac
Science, joining San Diego, Minneapolis, Miami and Nashville. "The
St. Louis Project Heartbeat" PAD program, which has been approved
by the City of St. Louis and Mayor Francis G. Slay, seeks to
provide this life saving technology to all its citizens, guests and
employees. The PAD program is being coordinated by the St. Louis
Fire Department, which in addition to planning the deployment of
AEDs, is reaching out to private citizens and organizations through
a public awareness campaign on the importance of defibrillation
therapy and the use of AEDs to treat victims of a massive heart
attack, also called sudden cardiac arrest ("SCA"). According to St.
Louis Fire Commissioner and Chief Sherman George, the goal of the
PAD project is to significantly increase local community cardiac
arrest survival rates by making AEDs more accessible in a wide
variety of settings and educating citizens about the Chain of
Survival, an emergency intervention process that includes early
defibrillation and CPR. "The St. Louis Fire Department has focused
on injury and illness prevention in many community outreach
programs. This program aims to dramatically improve SCA survival
rates in St. Louis," said Chief George. "This program is beneficial
not only to our citizens but to our fellow firefighters as well.
Heart attacks and SCA remain the number one killers of firefighters
today. "Our goal is to deploy hundreds of AEDs in public
facilities, highly trafficked public places and businesses
throughout St. Louis within the next few years," continued George.
"This is a true partnership and we look forward to working with
Cardiac Science in this effort. We chose Cardiac Science based on a
number of factors. We were impressed with their comprehensive
program and a demonstrable track record of PAD program successes in
other cities. In addition, we conducted an extensive review of all
AED products in the market and found that Cardiac Science's
Powerheart AEDs are robust, reliable, and very easy to use and best
suited the needs of the St. Louis Fire Department." About Cardiac
Science Cardiac Science develops, manufactures and markets
Powerheart(R)-brand public-access defibrillators (AEDs) and offers
comprehensive AED/CPR training and AED program management services
that facilitate successful deployments. The Company also makes its
AEDs on a private label basis for other leading medical companies
such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE
Healthcare. For more information, please visit
http://www.cardiacscience.com/, email Cardiac Science at or call
1-949-797-3800. This news release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. In addition, from time to time the company, or
its representatives, have made or may make forward looking
statements orally or in writing. The words "estimate," "potential,"
"intended," "expect," "anticipate," "believe," and similar
expressions or words are intended to identify forward looking
statements. Cardiac Science cautions that these statements are
subject to substantial risks and uncertainties and are qualified by
important factors that could cause actual results to differ
materially from those reflected by the forward- looking statements
and should not be relied upon by investors when making an
investment decision. Information on these and other factors is
detailed in the Company's Form 10-K for the year ending December
31, 2003, subsequent quarterly filings, and other documents filed
by the Company with the Securities and Exchange Commission. For
further information please contact: Matt Clawson (Investors), Allen
& Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or
Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science,
Inc., +1-949-797-3800, DATASOURCE: Cardiac Science, Inc. CONTACT:
Matt Clawson (Investors), Allen & Caron Inc, +1-949-474-4300, ,
for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing
Officer of Cardiac Science, Inc., +1-949-797-3800, Web site:
http://www.cardiacscience.com/
Copyright
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jul 2023 to Jul 2024